Bone Health

Hematology

Dermatology

Diabetes

Gastroenterology

Neurology

Oncology

Ophthalmology

Rare Disease

Rheumatology

News

Media

All Videos

Insights

Interviews

Peer Exchange

Podcasts

Compendia

Respiratory

Conferences

Conference Coverage

Conference Listing

CME/CE

Resources

Authors

Biosimilar Resources

Interactive Tools

WHEN CHOICE ARRIVES: Competition & Consequences

Subscribe

E-News

Print Subscription

BIOSIMILAR APPROVALS

Articles

The Increasing Access to Biosimilars Act of 2023 (HR 1352), a bill that would direct HHS to establish a demonstration project within Medicare that would establish a shared savings model for biosimilars, was introduced to the House of Representatives.

The Increasing Access to Biosimilars Act of 2023 Introduced to Congress

Newfoundland and Labrador is the latest Canadian province to implement a biosimilar switching policy, following in the footsteps of Ontario and 7 other jurisdictions.

Canadian Province Newfoundland and Labrador Adds Biosimilar Switching Policy

Posters presented by Alvotech at 2023 American Academy of Dermatology (AAD) annual meeting showcased proven bioequivalence and therapeutic equivalence candidate biosimilar AVT04 and reference ustekinumab (Stelara).

Favorable Equivalency Studies of Candidate Biosimilar AVT04 and Reference Ustekinumab

Representatives from Magellan Rx Management provided a detailed overview of current treatment options in ophthalmology and the impact that biosimilars could have during a session at AMCP 2023.

Getting Ophthalmic Biosimilars to Market Continues to Prove Difficult

About

Contact

Advisory Board

Do Not Sell My Information

Terms & Conditions

Privacy Policy

Center for Biosimilars®

Facebook

Twitter

LinkedIn

Business Practice

Business

Development

Legal

Policy

Practice

Regulatory

1rem

This new eBook from The Center for Biosimilars

® tells the compelling story of how biosimilar development and uptake have been affected by COVID-19. Read it and find out how biosimilars may emerge from the pandemic as a more powerful, more valuable force in lower-cost medicine.

The Disruptor: How Coronavirus Disease 2019 (COVID-19) Has Affected the Development and Uptake of Biosimilars

Are you ready for the upcoming 2020 transition of insulins and other therapeutic proteins to US regulation as biologics and biosimilars? Find out what you need to know about the regulatory change with a new ebook from The Center for Biosimilars®.

Preparing for the 2020 Regulatory Transition of Insulin and Other Therapeutic Proteins

Strategies for Successful Adoption of Biosimilars in Practice: Takeaways From the West Cancer Center Experience

Biosimilars 101:  Practice Concerns, Market Acceptance, and the Biosimilars Pipeline

Resources

Strategies for Successful Adoption of Biosimilars in Practice: Takeaways From the West Cancer Center Experience

Date:

Biosimilars 101: Practice Concerns, Market Acceptance, and the Biosimilars Pipeline

Date: